Madrigal Pharmaceuticals, Inc. (MDGL)
NASDAQ: MDGL · Real-Time Price · USD
325.63
-2.24 (-0.68%)
Mar 31, 2025, 1:13 PM EDT - Market open

Company Description

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.

The company offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH.

The company is headquartered in West Conshohocken, Pennsylvania.

Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals logo
Country United States
Founded 2011
Industry Biotechnology
Sector Healthcare
Employees 528
CEO William Sibold

Contact Details

Address:
Four Tower Bridge, Suite 200
West Conshohocken, Pennsylvania 19428
United States
Phone 267 824 2827
Website madrigalpharma.com

Stock Details

Ticker Symbol MDGL
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001157601
CUSIP Number 558868105
ISIN Number US5588681057
SIC Code 2834

Key Executives

Name Position
William J. Sibold Chief Executive Officer, President and Director
Dr. Rebecca A. Taub M.D. Founder, Chief Medical Officer, President of Research and Development and Director
Carole Huntsman Chief Commercial Officer
Mardi C. Dier Chief Financial Officer and Senior Vice President
Mark Underwood Senior Vice President of Business Planning and Operations
Ronald Filippo Chief Information Officer
Tina E. Ventura Chief Investor Relations Officer
Shannon Kelley General Counsel
Clint Wallace Chief Human Resources Officer
Edward Chiang Senior Vice President of Clinical and Technical Operations

Latest SEC Filings

Date Type Title
Mar 13, 2025 144 Filing
Mar 13, 2025 144/A Filing
Mar 12, 2025 144 Filing
Mar 11, 2025 8-K Current Report
Mar 5, 2025 144 Filing
Mar 3, 2025 144 Filing
Mar 3, 2025 144 Filing
Mar 3, 2025 144 Filing
Feb 28, 2025 144 Filing
Feb 27, 2025 144 Filing